GHDX Share Price

Open 27.89 Change Price %
High 27.89 1 Day -0.76 -2.72
Low 27.20 1 Week -2.02 -6.91
Close 27.23 1 Month -3.42 -11.16
Volume 121232 1 Year -2.94 -9.74
52 Week High 33.96
52 Week Low 22.00
GHDX Important Levels
Resistance 2 27.87
Resistance 1 27.61
Pivot 27.44
Support 1 26.85
Support 2 26.59
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DRYS 1.01 -36.48%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
BGMD 0.07 133.33%
LOCM 0.09 50.00%
NFEC 1.28 40.66%
BASI 0.90 28.57%
URRE 2.68 27.62%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
GRVY 20.96 23.15%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Genomic Health, Inc. (NASDAQ: GHDX)

GHDX Technical Analysis 4
As on 19th Jan 2017 GHDX Share Price closed @ 27.23 and we RECOMMEND Sell for LONG-TERM with Stoploss of 27.89 & Strong Sell for SHORT-TERM with Stoploss of 30.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
GHDX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
GHDX Other Details
Segment EQ
Market Capital 993752640.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.genomichealth.com
GHDX Address
GHDX
301 Penobscot Drive
Redwood City, CA 94063
United States
Phone: 650-556-9300
Interactive Technical Analysis Chart Genomic Health, Inc. ( GHDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Genomic Health, Inc.
GHDX Business Profile
Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.